Skip to the page

Data / Drug companies / Qilu Pharmaceutical Co., Ltd.

Qilu Pharmaceutical Co., Ltd.: 61 products in the FDA NDC directory, labeler code 67184

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Qilu Pharmaceutical Co., Ltd. (labeler code 67184) lists 61 products in the FDA National Drug Code Directory, covering 29 finished drugs by generic name. By type: 58 prescription drugs, 3 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 3, 2026.

The request: Watch Qilu Pharmaceutical Co., Ltd. (FDA labeler code 67184): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
67184
Products in commercial distribution
61
Packages
73
Finished drugs by generic name
29
Prescription products
58
Over the counter products
0
Flagged as original packager
53 of 53 products that carry the flag
Started marketing in the last 12 months
3
Earliest marketing start
September 8, 2014
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)5895.1%
Bulk ingredients34.9%

Products by type

TypeProductsShare
Prescription drugs5895.1%
Bulk ingredients34.9%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution1118%
Injection, powder, lyophilized, for solution1016.4%
Injection, powder, for solution914.8%
Tablet813.1%
Tablet, film coated58.2%
Injection46.6%
Powder34.9%
Capsule23.3%
Injection, suspension, liposomal23.3%
Kit23.3%
Tablet, film coated, extended release23.3%
Capsule, liquid filled23.3%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Doxorubicin hydrochloride67184-0624Injection, suspension, liposomalGeneric drugs (ANDA)February 3, 2026
Doxorubicin hydrochloride67184-0623Injection, suspension, liposomalGeneric drugs (ANDA)February 3, 2026
Olanzapine67184-0573Injection, powder, for solutionGeneric drugs (ANDA)November 11, 2025
Nicardipine Hydrochloride67184-0611Injection, solutionGeneric drugs (ANDA)October 28, 2025
Cyclosporine67184-0585Capsule, liquid filledGeneric drugs (ANDA)September 15, 2025
Cyclosporine67184-0584Capsule, liquid filledGeneric drugs (ANDA)September 15, 2025
Mirabgeorn67184-0572Tablet, film coated, extended releaseGeneric drugs (ANDA)June 30, 2025
Mirabegron67184-0571Tablet, film coated, extended releaseGeneric drugs (ANDA)June 30, 2025
Ganirelix Acetate67184-0574Injection, solutionGeneric drugs (ANDA)May 15, 2025
Micafungin67184-0590Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)April 3, 2025
Micafungin67184-0589Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)April 3, 2025
Icosapent Ethyl67184-0582CapsuleGeneric drugs (ANDA)January 1, 2025
Bumetanide67184-0594InjectionGeneric drugs (ANDA)September 19, 2024
Bumetanide67184-0593InjectionGeneric drugs (ANDA)September 19, 2024
Cetrorelix acetate67184-0605KitGeneric drugs (ANDA)April 16, 2024
Amikacin Sulfate67184-0570Injection, solutionGeneric drugs (ANDA)March 19, 2024
Amikacin Sulfate67184-0569Injection, solutionGeneric drugs (ANDA)March 19, 2024
Hydroxyurea67184-0607CapsuleGeneric drugs (ANDA)March 6, 2024
Melphalan Hydrochloride67184-0618KitGeneric drugs (ANDA)December 18, 2023
Gefitinib67184-0531Tablet, coatedGeneric drugs (ANDA)February 13, 2023
Imatinib mesylate67184-0533TabletGeneric drugs (ANDA)June 21, 2022
Imatinib mesylate67184-0532TabletGeneric drugs (ANDA)June 21, 2022
Pemetrexed67184-0504Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 25, 2022
Pemetrexed67184-0503Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 25, 2022
Bortezomib67184-0530Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)May 2, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.